Other diseases
IgG4-related disease
IgG4相关性疾病IgG4-RD
A group of immune-related diseases that can affect many organs, with inflamed tissue rich in IgG4-positive plasma cells that can lead to scarring and organ damage.
Definition adapted from MeSH (US National Library of Medicine)
Listed in China's first national rare-disease catalogue (2018, no. 56). National Health Commission 国卫医发〔2018〕10号
- hospitals in mainland China
- 46
- cities
- 24
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 23% of the world's English-language research papers on IgG4-related disease, 2021–2025 (13% in 2016–2020), and 55% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
46 hospitals in 24 cities
Order: papers led on IgG4-related disease, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on IgG4-related disease, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
- 47 papers led
- 12 papers ledNo open trial led
- 12 papers led
- 11 papers led
- 11 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 21
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 47 papers led1 hospital
- 22 papers led4 hospitals
- 18 papers led4 hospitals
- 13 papers led1 hospital
- 12 papers led2 hospitals
- 9 papers led2 hospitals
- 7 papers led3 hospitals
- 6 papers led3 hospitals
- 6 papers led3 hospitals
- 6 papers led3 hospitals
- 5 papers led1 hospital
- 4 papers led3 hospitals
- 4 papers led2 hospitals
- 3 papers led4 hospitals
- 3 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 1 paper led1 hospital
open trials on IgG4-related disease in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 16 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
- RecruitingA Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06978647
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
- Phase
- Phase 2/Phase 3
- Started
- 2025-07
- Registry
- NCT07068165
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT07104058
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingExploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07148791
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06285279
Age 18 years to 65 years (registered criteria)
Led by Jinling HospitalNanjing
- RecruitingSafety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06497361
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingSafety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06497387
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06794008
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingTreatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05789030
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNational Registry of IgG4-RD in China
- Phase
- Not given
- Started
- 2016-12
- Registry
- NCT03023371
Age not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Prospective Cohort Study of IgG4RD in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT01670695
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingStudy to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07222553
Age 2 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha
- Not yet recruitingA Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07593911
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- Not yet recruitingEfficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Phase
- Phase 3
- Started
- 2026-08
- Registry
- NCT07719543
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingNebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
- Phase
- Early phase 1
- Started
- 2026-10
- Registry
- NCT07806045
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingTripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07878585
Age 45 years to 79 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT06978738
Age 18 years to Not stated (registered criteria)
Led by Changzhou No.2 People's HospitalChangzhou
- Not yet recruitingAn Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07298590
Age 18 years to 70 years (registered criteria)
Led by Changhai HospitalShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Rare disease diagnosis and treatment guideline (2019 edition), written for the first national rare-disease catalogueNational Health Commission 国卫办医函〔2019〕198号, 2019-02-27
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.